Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Saved in:
| Title: | Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. |
|---|---|
| Authors: | Subbiah, V.1 (AUTHOR), Kreitman, R.J.2 (AUTHOR), Wainberg, Z.A.3 (AUTHOR), Cho, J.Y.4 (AUTHOR), Schellens, J.H.M.5 (AUTHOR), Soria, J.C.6 (AUTHOR), Wen, P.Y.7 (AUTHOR), Zielinski, C.C.8 (AUTHOR), Cabanillas, M.E.1 (AUTHOR), Boran, A.9 (AUTHOR), Ilankumaran, P.9 (AUTHOR), Burgess, P.10 (AUTHOR), Romero Salas, T.9 (AUTHOR), Keam, B.1,11 (AUTHOR) bhumsuk@snu.ac.kr |
| Source: | Annals of Oncology. Apr2022, Vol. 33 Issue 4, p406-415. 10p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.12.014 |
